OBJECTIVES: This prospective study focused on the evaluation of antiparasitic therapy in chronic Chagas' disease, monitored by PCR. PATIENTS AND METHODS: One hundred and eighty-one patients, all seropositive for Trypanosoma cruzi infection, underwent specific chemotherapy with benznidazole. Twelve patients were classified as young (2-19 years), 122 patients were classified as adults (20-39 years) and 47 patients were classified as seniors (>or=40 years). In total, 116 (64%) were asymptomatic and 65 (36%) were symptomatic. Patients were monitored for 90, 150 and 420 days after treatment by PCR and serology. RESULTS: Before treatment, 68% had a positive PCR result. PCR positivity was significantly more frequent in patients aged 2-19 years (P = 0.0007) and in short-term immigrants (P = 0.0076). No differences in PCR sensitivity were observed between samples of patients with chronic symptomatic or indeterminate Chagas' disease. All patients presented an early conversion of PCR results 90 days post-treatment. However, at the end of the follow-up period PCR had become positive in four patients (4 out of 58 patients; 6.9%) who had strictly adhered to the treatment and in one who did not complete the treatment. Only one patient showed an alternating PCR during follow-up. CONCLUSIONS: We conclude that PCR is a useful tool for the early detection of parasite susceptibility to benznidazole and for the post-treatment parasitological follow-up of patients with chronic Chagas' disease.
OBJECTIVES: This prospective study focused on the evaluation of antiparasitic therapy in chronic Chagas' disease, monitored by PCR. PATIENTS AND METHODS: One hundred and eighty-one patients, all seropositive for Trypanosoma cruzi infection, underwent specific chemotherapy with benznidazole. Twelve patients were classified as young (2-19 years), 122 patients were classified as adults (20-39 years) and 47 patients were classified as seniors (>or=40 years). In total, 116 (64%) were asymptomatic and 65 (36%) were symptomatic. Patients were monitored for 90, 150 and 420 days after treatment by PCR and serology. RESULTS: Before treatment, 68% had a positive PCR result. PCR positivity was significantly more frequent in patients aged 2-19 years (P = 0.0007) and in short-term immigrants (P = 0.0076). No differences in PCR sensitivity were observed between samples of patients with chronic symptomatic or indeterminate Chagas' disease. All patients presented an early conversion of PCR results 90 days post-treatment. However, at the end of the follow-up period PCR had become positive in four patients (4 out of 58 patients; 6.9%) who had strictly adhered to the treatment and in one who did not complete the treatment. Only one patient showed an alternating PCR during follow-up. CONCLUSIONS: We conclude that PCR is a useful tool for the early detection of parasite susceptibility to benznidazole and for the post-treatment parasitological follow-up of patients with chronic Chagas' disease.
Authors: M Carmen Thomas; Ana Fernández-Villegas; Bartolomé Carrilero; Concepción Marañón; Daniel Saura; Oscar Noya; Manuel Segovia; Belkisyolé Alarcón de Noya; Carlos Alonso; Manuel Carlos López Journal: Clin Vaccine Immunol Date: 2011-12-07
Authors: E C Sabino; A L Ribeiro; T H Lee; C L Oliveira; A B Carneiro-Proietti; A P Antunes; M M Menezes; B M Ianni; V M Salemi; L Nastari; F Fernandes; V Sachdev; D M Carrick; X Deng; D Wright; T T Gonçalez; E L Murphy; B Custer; M P Busch Journal: Eur J Heart Fail Date: 2015-02-10 Impact factor: 15.534
Authors: Cristina Vázquez; Elisa García-Vázquez; Bartolomé Carrilero; Marina Simón; Fuensanta Franco; Maria A Iborra; Luis J Gil-Gallardo; Manuel Segovia Journal: Am J Trop Med Hyg Date: 2020-05 Impact factor: 2.345
Authors: José M Ramos; Diego Torrús; Concepción Amador; Francisco Jover; Fabiola Pérez-Chacón; Yamileth Ponce; Francisco J Arjona; Elena Caro; Concepción Martínez-Peinado; Ingrid Gallegos; José M Cuadrado; Antonio Tello; Felix Gutiérrez Journal: Pathog Glob Health Date: 2012-10 Impact factor: 2.894
Authors: R Viotti; B Alarcón de Noya; T Araujo-Jorge; M J Grijalva; F Guhl; M C López; J M Ramsey; I Ribeiro; A G Schijman; S Sosa-Estani; F Torrico; J Gascon Journal: Antimicrob Agents Chemother Date: 2013-11-18 Impact factor: 5.191